Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Phase II study of intravenous melphalan (NSC-8806) in the treatment of patients with advanced squamous carcinoma of the head and neck

Abstract

The Illinois Cancer Center entered 25 patients on a phase II trial of intravenous melphalan treating patients with recurrent, metastatic or locally advanced and inoperable squamous cell carcinoma of the head and neck. All patients had bi-dimensionally measurable disease, at least a sixty day life expectancy, and adequate performance status (ECOG scale ≤2). All patients except one had received prior radiotherapy, chemotherapy or both. Melphalan dosage was 30 mg/m2 every three weeks. Twenty-four patients were evaluable for response. One patient with laryngeal carcinoma had a clinical complete response of a nodal metastasis. Four patients had stabilization of disease for one to three months. There was formidable toxicity, including neutropenia (ANC < 1000/μl 36%), and thrombocytopenia (< 50,000/μl 32%). There were no drug-related deaths. Melphalan administered intravenously does not appear to be efficacious therapy in patients with previously treated advanced head and neck squamous carcinomas.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Fletcher GH: Basic principles of the combination of irradiation and surgery. Int J Radiat Oncol Biol Phys 5:2091–2096, 1979

  2. 2.

    Kies MS, Gordon LI, Hauck WW, Krespi Y, Ossoff RH, Pecaro BC, Yuska C, Lamut CH, Brand WN, Chang SK, Shetty R, Sisson GA: Analysis of complete responders after initial treatment with chemotherapy in head and neck cancer. Otolaryngol Head Neck Surg 93(2): 199–205, 1985

  3. 3.

    Dreyfuss AI, Clark JR, Wright JE, Norris CM, Busse PM, Lucarini JW, Fallen BG, Casey D, Andersen JW, Klein R, Rosowsky A, Miller D, Frei E: Continuous infusion high dose leucovorin with 5-fluorouracil and cisplatin for untreated stage IV carcinoma of the head and neck. Ann Intern Med 112:167–172, 1990

  4. 4.

    Yokes EE, Weichselbaum RR, Lippman JM, Hong WK: Head and neck cancer. N Engl J Med 328:184–194, 1993

  5. 5.

    Bosanquet AG, Gilby ED: Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma. Eur J Cancer Clin Oncol 18(4):355–362, 1982

  6. 6.

    Spitzer G, Jagannath S, Dicke KA, Armitage J, Zander AR, Vellekoop L, Horwitz L, Cabanillas F, Zagars GK, Velasquez WS: High dose melphalan and total body irradiation with bone marrow transplantation for refractory malignancies. Eur J Cancer Clin Oncol 22:677–684, 1986

  7. 7.

    Lokhorst HM, Meuwissen OJ, Verdonck LF, Dekker AW: High-risk multiple myeloma treated with high dose melphalan. J Clin Oncol 10:47–51, 1992

Download references

Author information

Correspondence to Merrill S. Kies.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Kies, M.S., Grinblatt, D., Runge-Morris, M. et al. Phase II study of intravenous melphalan (NSC-8806) in the treatment of patients with advanced squamous carcinoma of the head and neck. Invest New Drugs 12, 45–47 (1994). https://doi.org/10.1007/BF00873235

Download citation

Keywords

  • Squamous Cell Carcinoma
  • Melphalan
  • Neutropenia
  • Squamous Carcinoma
  • Measurable Disease